CVS Health Corporation
CVSNYSEHealthcare● Active
$97.09
+$1.16(+1.21%)
Market Cap$123.9B
P/E Ratio—
52W High$98.43
52W Low$58.5
CVS Health Corporation (CVS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CVS · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
$2.57
Est. $2.18 · +17.9%
Revenue
$100.4B
Est. $94.99B · +5.7%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 6-Quarter EPS Beat Streak
CVS reports quarterly as a NYSE-listed Medical - Healthcare Plans company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | $1.85 | — | — | — | $100.2B | — |
| ▲ Q2 FY2026 | May 6, 2026 | $2.18 | $2.57 | +17.9% | $100.4B | $94.99B | +5.7% |
| ▲ Q1 FY2026 | Feb 10, 2026 | $1.00 | $1.09 | +9.0% | $105.7B | $103.7B | +1.9% |
| ▲ Q4 FY2025 | Oct 29, 2025 | $1.37 | $1.60 | +16.8% | $102.9B | $98.81B | +4.1% |
| ▲ Q3 FY2025 | Jul 31, 2025 | $1.46 | $1.81 | +24.0% | $98.92B | $94.53B | +4.6% |
| ▲ Q2 FY2025 | May 1, 2025 | $1.70 | $2.25 | +32.4% | $94.59B | $93.68B | +1.0% |
| ▲ Q1 FY2025 | Feb 12, 2025 | $0.91 | $1.19 | +30.2% | $97.71B | $97.09B | +0.6% |
| ▼ Q4 FY2024 | Nov 6, 2024 | $1.44 | $1.09 | -24.3% | $95.43B | $92.75B | +2.9% |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
$1.85
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Beat
EPS Actual
$2.57
EPS Est.
$2.18
EPS Surpr.
+17.9%
Revenue
$100.4B
Q1 FY2026
Feb 10, 2026Beat
EPS Actual
$1.09
EPS Est.
$1.00
EPS Surpr.
+9.0%
Revenue
$105.7B
Q4 FY2025
Oct 29, 2025Beat
EPS Actual
$1.60
EPS Est.
$1.37
EPS Surpr.
+16.8%
Revenue
$102.9B
Q3 FY2025
Jul 31, 2025Beat
EPS Actual
$1.81
EPS Est.
$1.46
EPS Surpr.
+24.0%
Revenue
$98.92B
Q2 FY2025
May 1, 2025Beat
EPS Actual
$2.25
EPS Est.
$1.70
EPS Surpr.
+32.4%
Revenue
$94.59B
Q1 FY2025
Feb 12, 2025Beat
EPS Actual
$1.19
EPS Est.
$0.91
EPS Surpr.
+30.2%
Revenue
$97.71B
Q4 FY2024
Nov 6, 2024Miss
EPS Actual
$1.09
EPS Est.
$1.44
EPS Surpr.
-24.3%
Revenue
$95.43B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $1.73 | $1.79 | $1.88 | 7 |
| Q3 FY2028 | $2.24 | $2.30 | $2.42 | 12 |
| Q2 FY2028 | $2.37 | $2.44 | $2.56 | 7 |
| Q1 FY2028 | $3.09 | $3.18 | $3.34 | 7 |
| Q4 FY2027 | $1.53 | $1.57 | $1.65 | 6 |
| Q3 FY2027 | $1.94 | $2.00 | $2.10 | 7 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $114B | $117B | $122B | 4 |
| Q3 FY2028 | $111B | $114B | $118B | 9 |
| Q2 FY2028 | $107B | $110B | $114B | 6 |
| Q1 FY2028 | $107B | $110B | $114B | 4 |
| Q4 FY2027 | $108B | $110B | $115B | 5 |
| Q3 FY2027 | $105B | $107B | $112B | 9 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 6, 2026 | +17.9% | $80.69 | $86.86 | +7.65% |
| ▲ Q1 FY2026 | Feb 10, 2026 | +9.0% | $75.77 | $75.62 | -0.20% |
| ▲ Q4 FY2025 | Oct 29, 2025 | +16.8% | $82.20 | $80.60 | -1.95% |
| ▲ Q3 FY2025 | Jul 31, 2025 | +24.0% | $62.30 | $62.10 | -0.32% |
| ▲ Q2 FY2025 | May 1, 2025 | +32.4% | $66.71 | $69.45 | +4.11% |
| ▲ Q1 FY2025 | Feb 12, 2025 | +30.2% | $55.00 | $63.22 | +14.95% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -24.3% | $55.34 | $61.61 | +11.33% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +5.8% | $58.34 | $56.47 | -3.21% |
Q2 FY2026+7.65%
Report Date
May 6, 2026
EPS Beat/Miss
+17.9%
Price Before
$80.69
Price After
$86.86
Q1 FY2026-0.20%
Report Date
Feb 10, 2026
EPS Beat/Miss
+9.0%
Price Before
$75.77
Price After
$75.62
Q4 FY2025-1.95%
Report Date
Oct 29, 2025
EPS Beat/Miss
+16.8%
Price Before
$82.20
Price After
$80.60
Q3 FY2025-0.32%
Report Date
Jul 31, 2025
EPS Beat/Miss
+24.0%
Price Before
$62.30
Price After
$62.10
Q2 FY2025+4.11%
Report Date
May 1, 2025
EPS Beat/Miss
+32.4%
Price Before
$66.71
Price After
$69.45
Q1 FY2025+14.95%
Report Date
Feb 12, 2025
EPS Beat/Miss
+30.2%
Price Before
$55.00
Price After
$63.22
Q4 FY2024+11.33%
Report Date
Nov 6, 2024
EPS Beat/Miss
-24.3%
Price Before
$55.34
Price After
$61.61
Q3 FY2024-3.21%
Report Date
Aug 7, 2024
EPS Beat/Miss
+5.8%
Price Before
$58.34
Price After
$56.47
Avg Beat Reaction+3.00%
Avg Miss Reaction+11.33%
Beat Rate7 / 8 quarters
Largest Move+14.95% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CVS ends December
CVS Health Corporation (CVS) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $2.57 — beating the analyst consensus of $2.18 by +17.9%. CVS has beaten EPS estimates for 6 consecutive quarters. The next CVS earnings date is expected around September 1, 2026.
Each quarter, investors track CVS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CVS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CVS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CVS earnings · 5 questionsCVS Health Corporation's next earnings report is expected around September 1, 2026. CVS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CVS historically reports after market close (AMC).
CVS earnings datewhen is CVS earningsCVS next earnings datewhen does CVS report earningsCVS earnings calendar
▸ Source: FMP · CVS Health Corporation SEC filings · US GAAP · CVS Health Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026